We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Studio Pictures Ltd is a UK-based film and TV production company founded by producers Adam Rolston and David Braithwaite in 2019. Specializing in creating high-quality British entertainment content, the company focuses on adapting books to screen and telling unique true-life stories that entertain and inspire both domestic and international audiences. With successful productions like "A Street Cat Named Bob," the company is building a strong brand and reputation in the industry. Studio Pictures has access to top creative talent and collaborates with major studios like Warner Bros, Sony Pictures, Lionsgate, and Studio Canal. The company is located at Twickenham Studios in Richmond, UK.
days to go: 17 investment: Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Bioepic is an app which enables users to easily and non-invasively measure their health status in just 30 seconds using just a smartphone. The app calculates pulse wave velocity, body temperature, blood pressure, heart rate variability chaos, vascular stiffness and the effectiveness of inhalers. 
days to go: Expired investment: £12,500
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £388,038
Redag Crop is an agrochemical discovery business focused on products that play a vital role in controlling the pests and diseases that threaten our global food supply. The growing population, expected to grow by 8 billion by 2020 and then 9 billion by 2050, will need more crops than the existing land can produce. Each hectare will need to produce 2.5 times as many crops as they do now. 
days to go: Expired investment: £1,250,000
Market Halls (MH) takes unloved public spaces and transforms them into destinations for all-day drinking and dining. MH claims to offer something for everyone, taking visitors seamlessly from breakfast through to late-night snacks. It argues that it has established three venues in Fulham, Victoria and the West End that have attracted crowds in excess of 1.04 million in 2019. MH asserts that it received a Net Promoter Score (NPS) of 62, generated £15 million in revenue in 2020, and has featured in publications such as The Telegraph, The Guardian and Independent. MH also stresses that it has a ‘Best in Class’ retention rate of 80% repeat business. It states it will use the investment to scale up its business with a new identity, new gold-dust venues and an improved customer offering.

Pitch Rated

60%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £787,240
Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.

Pitch Rated

66%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £488,450
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph